Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
The postantibiotic effect (PAE) was determined for two of the newer fluoroquinolones: DU-6859a and levofloxacin. All drugs (including ofloxacin control) had good PAE activity against Escherichia coli and Staphylococcus aureus. Only DU-6859a had PAE test conditions (< or = 0.5 mu/ml) that coincided with achievable clinical concentrations for all organisms tested. These data indicate that levofloxacin, like ofloxacin (PAEs, 1.0-2.9 h), could be administered once or twice daily and that the dosing of DU-6859a (PAEs, 1.6-2.4 h) might be extended to once every 24 h because of its documented PAE and its potency advantages as compared with levofloxacin and ofloxacin.
Department of Pathology, University of Iowa College of Medicine, Iowa City 52242.
A K
AK
Houston
R N
RN
Jones
D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D013293:Enterococcus faecalis / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D024841:Fluoroquinolones; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D015242:Ofloxacin / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D015363:Quinolones / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D064704:Levofloxacin; C076246:sitafloxacin; D015242:Ofloxacin